H.C. Wainwright downgraded Novocure to Neutral from Buy with a $25 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVCR:
- NovoCure (NASDAQ:NVCR) Nosedives on Disappointing Phase 3 Results
- Novocure: INNOVATE-3 trial of TTFields for OC did not meet primary endpoint
- DraftKings upgraded, Home Depot downgraded: Wall Street’s top analyst calls
- Novocure upgraded to Overweight from Neutral at Piper Sandler
- Novocure management to meet with Piper Sandler